Mounjaro vs. Orlistat
Mounjaro and Orlistat differ widely in purpose and efficacy. Mounjaro is a dual GIP and GLP-1 agonist for type 2 diabetes, offering significant HbA1c reductions and moderate weight loss. Orlistat, a lipase inhibitor, blocks fat absorption for modest weight loss but provides no glucose-related benefits. Side effects vary: Mounjaro causes nausea, while Orlistat is associated with gastrointestinal issues like oily stools. Mounjaro costs $1,135/month, far exceeding Orlistat’s $100/month. Neither drug currently faces shortages.
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Blocks the breakdown and absorption of dietary fat in the intestines. Unabsorbed fat is excreted in the stool, reducing calorie intake and promoting weight loss.
Common Side Effects
Oily or fatty stools, frequent bowel movements, flatulence with discharge, and abdominal discomfort.
Serious Potential Side Effects
Rare liver damage and malabsorption of fat-soluble vitamins (A, D, E, K), kidney problems, and severe allergic reactions